Alpa Laboratories Limited
NSE: ALPA BSE: ALPA
NSE
64.40
-1.61 (-2.44%)
Prev Close
66.01
Open Price
66.8
Volume
42,752
Today Low / High
62 / 66.8
52 WK Low / High
61 / 120.5
Range
61 - 68
BSE
61.23
-4.89 (-7.40%)
Prev Close
66.12
Open Price
68.9
Volume
5,906
Today Low / High
61.23 / 68.9
52 WK Low / High
61.18 / 124.88
Range
58 - 64
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 64.4 (target range: 61 - 68), reflecting a change of -1.61 (-2.43902%). On the BSE, it is listed at 61.23 (target range: 58 - 64), showing a change of -4.89 (-7.39564%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
27 Feb
65.55
0.70%
26 Feb
66.12
-0.83%
25 Feb
66.89
-3.09%
24 Feb
69.00
-5.20%
23 Feb
66.91
1.90%
20 Feb
68.73
-2.65%
19 Feb
72.00
-4.54%
18 Feb
71.89
-0.67%
17 Feb
66.97
5.69%
16 Feb
68.01
-1.53%
13 Feb
68.98
-1.93%
12 Feb
70.51
-2.17%
11 Feb
74.00
-2.64%
10 Feb
75.57
-1.84%
09 Feb
71.35
4.51%
Alpa Laboratories Limited Graph
Alpa Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Alpa Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 64.40, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 61.23 | 61.84 | 55.66 - 68.03 |
| 62.45 | 49.96 - 74.95 | ||
| 63.07 | 44.15 - 81.99 | ||
| Bearish Scenario | 61.23 | 60.62 | 54.56 - 66.68 |
| 60.01 | 48.00 - 72.01 | ||
| 59.39 | 41.58 - 77.21 |
Overview of Alpa Laboratories Limited
ISIN
INE385I01010
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
26,564
Market Cap
1,379,000,924
Last Dividend
0
Official Website
IPO Date
2007-08-06
DCF Diff
-51.53
DCF
118
Financial Ratios Every Investor Needs
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 112.45 Cr | 93.05 Cr | 19.40 Cr | 0.1725 | 0.00 Cr | 14.47 Cr | 2.55 Cr | 19.50 Cr | 9.27 | 28.10 Cr | 0.1734 |
| 2024-03-31 | 108.74 Cr | 74.60 Cr | 18.89 Cr | 0.1737 | 0.00 Cr | 1.57 Cr | 6.15 Cr | 16.78 Cr | 8.01 | 23.00 Cr | 0.1543 |
| 2023-03-31 | 92.41 Cr | 61.67 Cr | 30.74 Cr | 0.3327 | 0.00 Cr | 1.10 Cr | 6.75 Cr | 12.58 Cr | 5.98 | 17.44 Cr | 0.1362 |
| 2022-03-31 | 110.51 Cr | 76.11 Cr | 34.41 Cr | 0.3113 | 0.00 Cr | 1.72 Cr | 9.54 Cr | 14.09 Cr | 6.70 | 21.43 Cr | 0.1275 |
| 2021-03-31 | 96.41 Cr | 64.76 Cr | 31.66 Cr | 0.3284 | 0.00 Cr | 2.20 Cr | 20.79 Cr | 7.25 Cr | 3.44 | 13.03 Cr | 0.0752 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 2.19 Cr | 222.59 Cr | 51.16 Cr | 171.4341 Cr | 0.03 Cr | -2.19 Cr | 17.64 Cr | 20.60 Cr | 0.00 Cr | 0.00 Cr | 10.76 Cr | 46.6661 Cr |
| 2024-03-31 | 1.71 Cr | 182.37 Cr | 30.46 Cr | 151.9096 Cr | 5.25 Cr | 3.54 Cr | 13.67 Cr | 11.41 Cr | 6.44 Cr | 0.00 Cr | 9.92 Cr | 28.3165 Cr |
| 2023-03-31 | 8.81 Cr | 167.27 Cr | 32.69 Cr | 134.5775 Cr | 2.30 Cr | -6.51 Cr | 12.64 Cr | 6.96 Cr | 0.00 Cr | 0.00 Cr | -63.72 Cr | 29.6325 Cr |
| 2022-03-31 | 1.58 Cr | 155.24 Cr | 33.51 Cr | 121.7312 Cr | 5.85 Cr | 4.27 Cr | 15.46 Cr | 9.22 Cr | 0.00 Cr | 0.00 Cr | -61.23 Cr | 31.3834 Cr |
| 2021-03-31 | 1.80 Cr | 140.37 Cr | 32.73 Cr | 107.6413 Cr | 0.19 Cr | -1.61 Cr | 16.56 Cr | 8.73 Cr | 0.00 Cr | 0.00 Cr | -30.54 Cr | 32.7179 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 9.2373 Cr | -3.5130 Cr | -5.2465 Cr | -2.1424 Cr | 0.4779 Cr | 2.1880 Cr | -11.3797 Cr | 19.5031 Cr | -5.2465 Cr | 0.0000 Cr | -3.9744 Cr |
| 2024-03-31 | 3.6487 Cr | -13.3357 Cr | 2.5832 Cr | -2.7365 Cr | -7.1038 Cr | 3.1101 Cr | -6.3852 Cr | 16.7765 Cr | 2.9424 Cr | 0.0000 Cr | -1.0241 Cr |
| 2023-03-31 | 8.9044 Cr | 2.1275 Cr | -3.7932 Cr | 7.7784 Cr | 7.2387 Cr | 8.8139 Cr | -1.1260 Cr | 15.6805 Cr | -3.5696 Cr | 0.0000 Cr | 2.8224 Cr |
| 2022-03-31 | 9.9403 Cr | -15.6096 Cr | 5.4425 Cr | 7.7494 Cr | -8.9348 Cr | 1.5752 Cr | -2.1909 Cr | 19.5601 Cr | 5.6616 Cr | 0.0000 Cr | 1.0962 Cr |
| 2021-03-31 | -1.7000 Cr | 5.8600 Cr | 0.1900 Cr | -4.9200 Cr | 4.3403 Cr | 10.5100 Cr | -3.2200 Cr | 10.7900 Cr | 0.2636 Cr | 0.0000 Cr | -4.0093 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 29.05 Cr | 25.94 Cr | 3.11 Cr | 0.1071 | 0.86 Cr | 1.90 Cr | 0.90 | 1.51 Cr | 0.0655 |
| 2025-09-30 | 26.26 Cr | 21.43 Cr | 4.83 Cr | 0.1840 | -2.91 Cr | 0.11 Cr | 0.05 | 0.82 Cr | 0.0043 |
| 2025-06-30 | 19.11 Cr | 12.69 Cr | 6.42 Cr | 0.3362 | -0.13 Cr | 11.77 Cr | 5.59 | 12.37 Cr | 0.6158 |
| 2025-03-31 | 39.92 Cr | 34.07 Cr | 5.85 Cr | 0.1465 | -0.39 Cr | -2.12 Cr | -1.01 | 2.67 Cr | -0.0532 |
| 2024-12-31 | 26.15 Cr | 16.18 Cr | 9.97 Cr | 0.3813 | 0.19 Cr | 8.90 Cr | 4.23 | 9.54 Cr | 0.3404 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 0.67 Cr | 138.31 Cr | 138.98 Cr | 37.29 Cr | 16.44 Cr | 207.32 Cr | 21.05 Cr | 237.63 Cr | 54.31 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 112.69 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -171.43 Cr |
| 2025-03-31 | 2.19 Cr | 110.50 Cr | 112.69 Cr | 50.68 Cr | 17.64 Cr | 191.18 Cr | 20.60 Cr | 222.59 Cr | 51.16 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 109.17 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -164.61 Cr |
| 2024-09-30 | 0.11 Cr | 110.48 Cr | 110.59 Cr | 0.58 Cr | 14.72 Cr | 177.37 Cr | 10.89 Cr | 198.97 Cr | 34.36 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 11.77 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | -2.17 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 8.90 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 7.69 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 5.10 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,752.50 | ₹4,204,834,534,925.00 | ₹3,919,016.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,403.50 | ₹1,699,928,052,030.00 | ₹300,339.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,369.20 | ₹1,478,735,816,448.00 | ₹231,761.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,294.40 | ₹1,077,692,658,712.00 | ₹1,052,141.00 |
| Lupin Limited | LUPIN | ₹2,311.10 | ₹1,056,272,077,300.00 | ₹580,904.00 |
| Mankind Pharma Limited | MANKIND | ₹2,245.50 | ₹926,953,789,176.00 | ₹545,012.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹906.90 | ₹912,553,605,531.00 | ₹518,610.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,210.40 | ₹703,002,284,479.00 | ₹888,443.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,566.00 | ₹665,498,790,000.00 | ₹54,260.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,123.30 | ₹599,196,977,750.00 | ₹315,603.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,065.00 | ₹574,947,259,830.00 | ₹2,261,423.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,513.00 | ₹383,854,481,834.00 | ₹115,864.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,967.80 | ₹370,783,944,907.00 | ₹82,523.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,077.40 | ₹333,479,924,060.00 | ₹259,727.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,445.30 | ₹273,989,192,062.00 | ₹128,185.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,801.00 | ₹220,025,000,000.00 | ₹7,555.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,310.00 | ₹212,864,741,390.00 | ₹350,318.00 |
| Eris Lifesciences Limited | ERIS | ₹1,360.40 | ₹185,309,458,516.00 | ₹144,678.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹956.25 | ₹171,273,813,188.00 | ₹1,073,075.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,096.00 | ₹168,020,226,344.00 | ₹39,142.00 |
| Granules India Limited | GRANULES | ₹574.40 | ₹139,388,910,470.00 | ₹468,097.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹705.25 | ₹138,626,143,201.00 | ₹58,524.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹850.35 | ₹134,669,715,212.00 | ₹109,605.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,672.90 | ₹127,159,966,238.00 | ₹90,254.00 |
| Cohance Lifesciences Limited | COHANCE | ₹303.20 | ₹115,994,356,848.00 | ₹708,355.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹914.35 | ₹112,223,661,600.00 | ₹57,229.00 |
| Viyash Scientific Limited | VIYASH | ₹199.94 | ₹87,214,939,466.00 | ₹1,642,591.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,987.60 | ₹82,791,077,663.00 | ₹22,174.00 |
| Strides Pharma Science Limited | STAR | ₹842.45 | ₹77,650,902,909.00 | ₹213,842.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹474.45 | ₹72,639,271,418.00 | ₹129,501.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹705.75 | ₹63,974,324,918.00 | ₹179,889.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹323.55 | ₹63,280,496,567.00 | ₹233,105.00 |
| FDC Limited | FDC | ₹372.05 | ₹60,573,491,752.00 | ₹125,826.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹125.92 | ₹40,863,758,361.00 | ₹481,526.00 |
| Innova Captab Limited | INNOVACAP | ₹664.30 | ₹38,014,520,335.00 | ₹27,921.00 |
| Suven Life Sciences Limited | SUVEN | ₹141.99 | ₹32,934,838,780.00 | ₹224,892.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹357.30 | ₹32,610,771,000.00 | ₹127,791.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹296.10 | ₹32,264,614,967.00 | ₹76,769.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹600.10 | ₹30,436,534,911.00 | ₹94,277.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,805.80 | ₹29,866,153,287.00 | ₹7,962.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹278.55 | ₹27,933,692,046.00 | ₹45,963.00 |
Key Executives
Chief Financial Officer
Bakulesh C. Shah
Gender: male
Year Born: 1961
Chairman of the Board
Mahendra Singh Chawla
Gender: male
Year Born: 1942
MD & Director
Paresh Chawla
Gender: male
Year Born: 1975
Executive Whole-Time Director
Pravin C. Shah
Gender: male
Year Born: 1948
Executive Whole-Time Director
Vitthal Kothana
Gender: male
Year Born: 1957
Whole Time Director
Shitul Shah
Gender: male
Year Born: 1979
Company Secretary & Compliance Officer
Srashti Chopra
Gender: female
Year Born:
FAQs about Alpa Laboratories Limited
Who is the CEO of the company?
The CEO is Mahendra Singh Chawla.
What is the current market price of the stock?
The current price is ₹65.54.
What is the 52-week price range?
The range is ₹61-120.5.
What is the market capitalization of the company?
The market capitalization is ₹137.90 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 11.83.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Alpa Laboratories Limited (ISIN: INE385I01010) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹137.90 crores and an average daily volume of 26,564 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.